Day: March 22, 2024

Flow Capital Announces Additional $2.3 Million Tranche of Non-Convertible Debenture Transaction

Flow Capital Announces Additional $2.3 Million Tranche of Non-Convertible Debenture Transaction

TORONTO, March 22, 2024 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW) (“Flow Capital” and “Company”), a leading provider of flexible growth capital and alternative debt solutions, is pleased to announce that it has completed a tranche of its previously disclosed non-convertible loan transaction in the principal amount of $2.3 million (the “Loans”). The Loans will be evidenced by unsecured, non-convertible debentures (the “Debentures”) issued by the Company to the Lenders pursuant to the terms of a debenture indenture entered between the Company and Olympia Trust Company, as debenture trustee. The net proceeds of the Loans will be used by the Company to fund investments and for general corporate purposes. About Flow Capital Flow Capital Corp. is a diversified alternative asset investor and advisor, specializing in providing minimally...

Continue reading

Bombardier Announces Pricing of its New Issuance of Senior Notes due 2031

Bombardier Announces Pricing of its New Issuance of Senior Notes due 2031

MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has successfully priced its offering of US$750 million aggregate principal amount of new Senior Notes due July 1, 2031. The new Senior Notes will carry a coupon of 7.250% per annum and will be sold at 99.75% of par (the “New Notes”). The issuance of the New Notes is expected to close on or about April 4, 2024, subject to customary closing conditions. Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to finance the offer to purchase (the “2026 Tender Offer”) up to US$550 million aggregate purchase amount (exclusive of accrued and unpaid interest) of its outstanding 7.125% Senior Notes due 2026 (the “2026 Notes”), of which there is US$1,001 million aggregate principal amount outstanding...

Continue reading

Bombardier Announces Conditional Notice of Partial Redemption for US$200,000,000 of its 7.875% Senior Notes due 2027

Bombardier Announces Conditional Notice of Partial Redemption for US$200,000,000 of its 7.875% Senior Notes due 2027

MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has issued a conditional notice of partial redemption for US$200 million principal amount of its outstanding 7.875% Senior Notes due 2027 (the “Notes”). As set forth in the conditional notice of partial redemption issued today in respect of the Notes, the redemption date is April 22, 2024 (the “Redemption Date”), and the redemption price is 100.00% of the principal amount redeemed, plus accrued and unpaid interest. The redemption of the Notes is subject to and conditioned upon Bombardier completing a new offering of debt securities in the aggregate principal amount of not less than US$750 million before the Redemption Date; however, Bombardier may delay or waive this condition in its sole and absolute discretion.  On March 22, 2024,...

Continue reading

Tenaris Files 2023 Annual Report, 2023 Sustainability Report, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders

Tenaris Files 2023 Annual Report, 2023 Sustainability Report, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders

LUXEMBOURG, March 22, 2024 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) filed today its 2023 Annual Report and its 2023 Sustainability Report with the Luxembourg Stock Exchange, with the U.S. Securities and Exchange Commission (SEC), and with the other securities regulators of the markets where its securities are listed. These reports (which contain the financial and non-financial information required by applicable Luxembourg law for the year ended December 31, 2023, including Tenaris’s consolidated financial statements as of and for the year ended December 31, 2023, Tenaris’s annual accounts as at December 31, 2023, and their related external auditors’ reports and consolidated management report and certifications) is available on the Luxembourg Stock Exchange’s website at www.bourse.lu/regulated-information-oam,...

Continue reading

Glacier Reports Year End 2023 Results

Glacier Reports Year End 2023 Results

VANCOUVER, British Columbia, March 22, 2024 (GLOBE NEWSWIRE) — Glacier Media Inc. (TSX: GVC) (“Glacier” or the “Company”) reported revenue and earnings for the year ended December 31, 2023. SUMMARY RESULTS (thousands of dollars)     except share and per share amounts     2023       2022             Revenue   $ 154,940     $ 176,012   EBITDA (1)   $ (4,169 )   $ 3,083   EBITDA (1) margin     (2.7 %)     1.8 % EBITDA (1) per share   $ (0.03 )   $ 0.02   Capital expenditures   $ 4,316     $ 4,945   Net loss attributable to common shareholder   $ (99,250 )   $ (29,553 ) Net loss attributable to common shareholder per share   $ (0.76 )   $ (0.22 )           Weighted average shares outstanding, net     131,198,520       132,558,408                   (1) EBITDA is considered a non-GAAP measure. Refer to “EBITDA...

Continue reading

Cranstown Signs Letter of Intent to Acquire J2 Metals Inc.

Cranstown Signs Letter of Intent to Acquire J2 Metals Inc.

VANCOUVER, British Columbia, March 22, 2024 (GLOBE NEWSWIRE) — Cranstown Capital Corp. (“CRAN” or the “Company”), a capital pool company pursuant to Policy 2.4 (“TSXV Policy 2.4”) of the TSX Venture Exchange (the “TSXV”), announces that it has entered into a non-binding letter of intent dated March 21, 2024 (the “LOI”) with J2 Metals Inc. (“J2”) whereby CRAN will acquire all of the issued and outstanding securities of J2 by way of a share exchange, amalgamation or such other form of business combination as the parties may determine (the “Proposed Transaction”). The Proposed Transaction is intended to constitute the Company’s “Qualifying Transaction” within the meaning of TSXV Policy 2.4.‎ Upon successful completion of the Proposed Transaction, it is anticipated that the Company will be listed as a Tier 2 Mining issuer on the TSXV...

Continue reading

DIRTT Adopts Shareholder Rights Plan and Enters Into Support Agreement

DIRTT Adopts Shareholder Rights Plan and Enters Into Support Agreement

CALGARY, Alberta, March 22, 2024 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (TSX: DRT; OTC: DRTTF), a leader in industrialized construction, announced today that its Board of Directors has adopted the shareholder rights plan announced on March 19, 2024 and has also entered into a support agreement with DIRTT’s largest shareholder, 22NW Fund, LP. As previously announced, the rights plan is substantially similar to the rights plan adopted by the Company in 2021 and is intended to limit further concentration of ownership of the company. While the rights plan has been approved by the Board of Directors with one director dissenting and is now in effect, it remains subject to shareholder ratification within six months of its adoption. The date and time of the special meeting of shareholders to ratify the rights plan will be...

Continue reading

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) — AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights. Recent Highlights   ● Stockholders approved transactions for merger with Serina Therapeutics, Inc.   ● Obtained $4.4 million addition to line of credit from Juvenescence Limited   ● Preferred Stock converted into Common Stock   ● Completed reverse stock split at a ratio of 1 for 35.17       Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness and Conversion to Common Stock During July 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant...

Continue reading

Major Announces Application for Partial Revocation Order

Major Announces Application for Partial Revocation Order

VANCOUVER, British Columbia, March 22, 2024 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) has applied to the British Columbia Securities Commission (“BCSC”) for a partial revocation of the failure-to-file cease trade order (“FFCTO”) that was issued by the BCSC against the company on January 12, 2023, for failing to file certain outstanding continuous disclosure documents in a timely manner. If the partial revocation order is granted, the company intends to complete a non-brokered private placement of up to thirty million units (“Units”) issued at a price of $0.025 per Unit for gross proceeds of up to $750,000. Each Unit will be comprised of one common share (each a “Share”) and one transferable common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof...

Continue reading

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

Leading Contract Research Organization to carry out pharmacological studies, part of planned FDA Investigational New Drug (IND) application TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strategic service agreement with Vivox Ltd. (“Vivox”), a leading provider of animal testing and services in Israel to biotech and pharmaceutical companies. This large-scale animal testing represents a significant step towards filing an Investigational New Drug (IND) application in the US for NurExone’s ExoPTEN therapy for spinal cord injury (SCI). Under the terms of the agreement, Vivox will provide Contract Research Organization (CRO) services to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.